912
Views
30
CrossRef citations to date
0
Altmetric
Review

MEK inhibitors in oncology: a patent review (2015-Present)

, &
Pages 887-906 | Received 10 Dec 2016, Accepted 05 Jun 2017, Published online: 19 Jun 2017

References

  • Issa AM. Personalized Medici ne and the Practice of Medicine in the 21st Century. Mcgill J Med. 2007;10(1):53–57.
  • PMI Cohort Program announces new name: the All of Us Research. National Institute of Health, U.S. 2016. [accessed 02.Dec.2016] Available from:https://www.nih.gov/AllofUs-research-program/pmi-cohort-program-announces-new-name-all-us-research-program
  • Heppt MV, Tietze JK, Graf SA, et al. Combination therapy of melanoma using kinase inhibitors. Curr Opin Oncol. 2015;27(2):134–140.
  • Asati V, Mahapatra DK, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314–341.
  • Qazi AK, Hussain A, Hamid A, et al. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies. Anticancer Agents Med Chem. 2013;13(10):1552–1564.
  • Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Oncol Res Treat. 2003;25(6):511–518.
  • Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–3310.
  • Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer. 2003;104(5):527–532.
  • Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23:10–24.
  • Pelekanou V, Kampa M, Kafousi M, et al. Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer. 2008;8:76.
  • Pathway Central: Ras Pathway, SABiosciences, Qiagen. [cited 2017 Jan 27]. Available from: http://www.sabiosciences.com/pathway.php?sn=Ras_Pathway
  • Mendoza MC, Emrah EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320–328.
  • Lodish H, Berk A, Zipursky SL, et al. Receptor tyrosine kinases and ras. Section 20.4-Molecular Cell Biology. 4th ed. New York: W. H. Freeman and Company; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK21475/
  • Castellano E, Downward J. RAS interaction with PI3K more than just another effector pathway. Genes Cancer. 2011;2(3):261–274.
  • Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875–885.
  • Rajalingam K, Schreck R, Rapp UR, et al. Ras oncogenes and their downstream targets. Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research. 2007;1773:1177–1195.
  • Cox AD, Der CJ. Ras history: the saga continues. Ras History, Small Gtpases. 2010;1(1):2–27.
  • Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457–2467.
  • Mark GE, Rapp UR. Primary structure of v-raf: relatedness to the src family of oncogenes. Sci. 1984;224(4646):285–289.
  • Jansen HW, Rückert B, Lurz R, et al. Two unrelated cell-derived sequences in the genome of avian leukemia and carcinoma inducing retrovirus MH2. Embo J. 1983;2(11):1969.
  • Avruch J, Zhang XF, Kyriakis JM. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci. 1994;19(7):279–283.
  • Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res. 1999;253(1):34–46.
  • Schreck R, Rapp UR. Raf kinases: oncogenesis and drug discovery. Int J Cancer. 2006;119(10):2261–2271.
  • Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4(4):677–685.
  • Strumberg D, Seeber S. Raf kinase inhibitors in oncology. Oncol Res Treat. 2005;28(2):101–107.
  • Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol. 2005;5(4):350–356.
  • Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6(4):313–319.
  • Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 1996;87(4):629–638.
  • Nantel A, Huber M, Thomas DY. Localization of endogenous Grb10 to the mitochondria and its interaction with the mitochondrial-associated Raf-1 pool. J Biol Chem. 1999;274(50):35719–35724.
  • Yuryev A, Ono M, Goff SA, et al. Isoform-specific localization of A-RAF in mitochondria. Mol Cell Biol. 2000;20(13):4870–4878.
  • The Cancer Genome Atlas Data Portal. National Cancer Institute. National Institutes of Health, USA. [cited 2016 Nov 7]. Available from: https://tcga-data.nci.nih.gov/docs/publications/tcga/?
  • Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nat. 2010;464(7287):431–435.
  • Zhou J, Wu Z, Wong G, et al. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun. 2017;8:13897.
  • Morris EJ, Jha S, Restaino CR, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013;3(7):742–750.
  • Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011;17(5):989–1000.
  • LoRusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23(23):5281–5293.
  • Trujillo JI. MEK inhibitors: a patent review 2008–2010. Expert Opin Ther Pat. 2011;21(7):1045–1069.
  • Novartis. Compounds and compositions as inhibitors of MEK. US20160136150A1; 2016.
  • Shanghai Hengrui Pharm Co Ltd. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof. EP3061747; 2016.
  • Shanghai Kechow Pharma Inc. Benzoheterocyclic compounds and use thereof. US20160235721; 2016.
  • Array BioPharma, Inc. Preparation of and formulation comprising a MEK inhibitor US20160168103A1; 2016.
  • Ardea Biosciences Inc. N-(arylamino)sulfonamide derivative comprising MEK inhibitor polymorphous form, and composition, use method and method for preparing the same. JP2015078199; 2015.
  • The Asan Foundation. Substituted pyridinone compounds as MEK inhibitors. US20160108041A1; 2016.
  • Lupin Ltd. Pyridopyrimidine derivatives as MEK inhibitors. WO2016035008A1; 2016.
  • Exelixis. MEK inhibitors and methods of their use. US20150141399A1; 2015.
  • Allomek Therapeutics. Novel MEK inhibitors for treating cardiomyopathies and related conditions. US20150250762A1; 2015.
  • Asana Biosciences. Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/MTOR pathways. EP2984088; 2016.
  • Jiangsu Hengrui Medicine Co Ltd. p-toluenesulfonate for mek kinase inhibitor, and crystal form thereof and preparation method therefor. WO2016155473; 2016.
  • The Regents of the University of Michigan. Dual MEK/PI3K inhibitors and therapeutic methods using the same. US20160002212; 2016.
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Pharmaceutical composition of MEK inhibitor and preparation method thereof. WO2016188472; 2016.
  • Kyoto University. Agent for preventing and/or treating amyotrophic lateral sclerosis. WO2016114322A1; 2016.
  • Tyrnovo Ltd. Combinations of IRS/STAT3 dual modulators and anti-cancer agents for treating cancer. WO2016125169; 2016.
  • Stichting Het Nl Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis. Combinations of inhibitors of MEK, EGFR and ERBB2 in the treatment of KRAS-MUTANT LUNG CANCER and KRAS-mutant colon cancer. EP2968564; 2016.
  • Novartis. Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway US20150105417 (2015).
  • Novartis. Pharmaceutical combinations. US20150306101; 2015.
  • Genentech. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases. US20150111869A1 (2015).
  • Genentech. Compositions for treating cancer using PD-1 AXIS binding antagonists and MEK inhibitors. WO2016011160 (2016).
  • The board of regents of the University of Texas system. Treatment for melanoma. WO2015009591 (2015).
  • Hoffmann-La Roche. Combinations of PI3K inhibitor and MEK inhibitor. JP2015038110 (2015).
  • Sanofi. Methods for treating cancer using PI3K inhibitor and MEK inhibitor. US20150031882 (2015).
  • Stichting Het Nederlands Kanker Instituut. P90RSK in combination with RAF/ERK/MEK. WO2015041534 (2015).
  • Takeda Pharmaceutical. Administration of a RAF inhibitor and a MEK inhibitor in the treatment of melanoma. EP2830664 (2015).
  • GlaxoSmithKline. Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors. US20150111904 (2015).
  • Novartis. Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer. US20160367662; 2016.
  • Novartis. Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRAF inhibitor. US20160089434A1(2016).
  • Combination therapy of a MEK inhibitor and IGF1R inhibitor. CN104487089 (2015).
  • Combination. CN104382906 (2015).
  • Memorial Sloan-Kettering Cancer Center. Treatment of H-RAS driven tumors. WO2015164862 (2015).
  • The Regents of The University of California. Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use. SG11201507477X (2015).
  • Univ Tennessee Res Foundation. Compounds for treatment of cancer. EP2964028 (2016).
  • Merck. Compositions and methods for MEK inhibitor combination therapy in the treatment of cancer. WO2016014390A1 (2016).
  • Novartis. Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer. EP3079698 (2016).
  • Biomed Valley Discoveries Inc. Cancer treatments using combinations of MEK type 1 and ERK inhibitors. US20160310477 (2016).
  • Biomed Valley Discoveries Inc. Cancer treatments using combinations of type 2 MEK and ERK inhibitors. US20160367539; 2016.
  • Crystal Pharmatech Co Ltd. CDK inhibitor, eutectic crystal of MEK inhibitor, and preparation method therefor. WO2016155670 (2016).
  • Merrimack Pharmaceuticals Inc. Combination therapies comprising Anti-Erbb3 agents. US20160326262 (2016).
  • Verastem Inc. Methods and compositions for treating abnormal cell growth. US20160346282; 2016.
  • Garraway LA, Emery C, Garcia-Echeverria C MEK Mutations Conferring Resistance to MEK Inhibitors. US20150346204A1(2015).
  • Massachusetts Institute of Technology. Methods of Reducing Kinase Inhibitor Resistance. US20160067250A1 (2016).
  • Crown Bioscience. Methods for determining responsiveness to MEK/ERK inhibitors. WO2015149721A1 (2015).
  • Bayer Pharma. Biomarkers for determining effective response of treatments of hepatocellular carcinoma (HCC) patients. WO2013178581A1(2016).
  • Garraway LA, Emery C, Wagle N MEK1 Mutation Conferring Resistance to RAF and MEK. Inhibitors US20160216266 (2016).
  • Memorial Sloan-Kettering Cancer Center. DDX43 as a biomarker of resistance to MEK1/2 inhibitors. 2015035146A2 (2015).
  • Yonsei University. Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same. US20160346329; 2016.
  • Grilley-Olson JE, Bedard PL, Fasolo A, et al. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Invest New Drugs. 2016;34(6):740–749.
  • Duncan KE, Chang LY, Patronas M. MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity. Eye. 2015;29(8):1003–1012.
  • Rinehart J, Adjei AA, LoRusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22(22):4456–4462.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.